Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Intra-individual comparison of long-term outcomes between combined and indirect bypass surgery in adult moyamoya disease.
Acta Neurochir (Wien)
January 2025
Department of Neurosurgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.
Purpose: Bypass surgery is regarded as the standard treatment option for symptomatic and hemodynamically unstable moyamoya disease (MMD). However, there is ongoing debate about the most effective type of bypass surgery. We aimed to analyze the long-term outcomes of combined and indirect bypasses for MMD patients through intra-individual comparisons.
View Article and Find Full Text PDFPublic Health.
Alzheimers Dement
December 2024
Center for Life Ethics, University of Bonn, Bonn, Germany.
Background: In recent years, research on risk estimation and early detection of Alzheimer's disease (AD) advanced swiftly. Studies are investigating the likelihood of developing Alzheimer's dementia (ADD), even during asymptomatic, preclinical, and prodromal stages of AD. Particular hope is pinned on blood-based biomarkers as these are less invasive than other methods such as lumbar puncture and Positron Emission Tomography (PET)-scan.
View Article and Find Full Text PDFSystematic Review of COVID-19 and COVID-19 mRNA Vaccine Myocarditis in Athletes: Incidence, Diagnosis, Prognosis, and Return-to-Play Principles.
Clin J Sport Med
January 2025
Lake Erie College of Osteopathic Medicine, Bradenton, Florida.
Objective: The purpose of this systematic review is to evaluate the original peer-reviewed studies on athletes who developed myocarditis after coronavirus disease (COVID-19) infection or after COVID-19 mRNA vaccination. Both entities likely have an immunologic component. We discuss elite, professional, college, and adolescent athletes.
View Article and Find Full Text PDFBackground: Amyloid-plaque removal by monoclonal antibody therapies slows progression in symptomatic Alzheimer's disease (AD), but effects on preventing the onset of symptoms and dementia in asymptomatic people with amyloid plaques are unknown. We report the final primary and secondary outcomes of the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) trial to evaluate amyloid-plaque removal in delaying disease progression, including symptom onset, in symptomatic and asymptomatic dominantly inherited Alzheimer's disease (DIAD) individuals treated for up to a decade.
Method: This double-blind, phase 2/3 trial (2012-2019), followed by open-label extension (OLE), investigated varying gantenerumab doses up to 1500 mg subcutaneous q2 weeks [NCT01760005].
Developing Topics.
Alzheimers Dement
December 2024
Washington University in St. Louis, St. Louis, MO, USA.
Background: Anti-amyloid monoclonal antibody therapies for AD have documented plaque removal on amyloid PET scans. We evaluate the findings for amyloid PET, tau PET, FDG PET and volumetric MRI over the course the open label extension (OLE) for the DIAN-TU gantenerumab treatment, compared to the last imaging obtained prior to the OLE (to evaluate for potential rebound effects) and in comparison to longitudinal imaging in the DIAN Observational study.
Method: This double-blind, phase 2/3 trial (2012-2019), followed by open-label extension (OLE), investigated varying gantenerumab doses up to 1500 mg SQ q2 weeks [NCT NCT01760005].
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!